Core Viewpoint - The company reported its financial results for 2024 and Q1 2025, showing strong growth in revenue and net profit, driven by its proprietary brands and improved cash flow [1][2][3] Financial Performance - For 2024, revenue reached 1.77 billion, a year-on-year increase of 29.3%, with net profit attributable to shareholders at 110 million, up 94.6% [1] - In Q1 2025, revenue was 570 million, reflecting a 54.2% year-on-year growth, and net profit attributable to shareholders was 30 million, increasing by 113.9% [1] - The company proposed a cash dividend of 5 yuan per 10 shares and a stock bonus of 4 shares for every 10 shares held [1] Profitability and Cost Structure - The gross margin for 2024 was 44.6%, up 4.3 percentage points, while the net profit margin was 6.0%, an increase of 2.0 percentage points [1] - Sales expense ratio rose to 29.8%, up 2.0 percentage points due to increased marketing costs from business growth; management expense ratio decreased to 5.6%, down 1.3 percentage points; R&D expense ratio was 1.5%, down 0.3 percentage points [1] Operational Efficiency - By the end of 2024, accounts receivable stood at 200 million, a 17.6% increase year-on-year; net cash flow from operating activities improved significantly to 330 million, attributed to optimized inventory turnover and reduced stock levels [1] Brand Performance - The proprietary brand "Zhenjia" showed remarkable growth, with revenue of 480 million in 2024, a 90.1% increase, and a gross margin of 66.9% [2] - The brand management segment generated 500 million in revenue, a 212.24% increase, although its gross margin decreased to 30.5% [2] Channel Performance - Online sales reached 1.71 billion, up 26.7%, with a gross margin of 60.5%; offline sales were 50 million, a staggering 295.34% increase, but with a gross margin decline to 43.6% [2] Strategic Developments - The company’s proprietary brands have significantly contributed to performance, with "Zhenjia" and "Ficui" achieving over 100% growth in GMV across multiple channels [3] - The brand management business has attracted notable partners, enhancing GMV growth for brands like Bayer and Aveeno, while also expanding into personal care and health products [3] Future Outlook - The company has revised its profit forecasts for 2025-2027, expecting net profits of 170 million, 220 million, and 270 million respectively, with corresponding PE ratios of 47, 37, and 30 [3]
若羽臣(003010):绽家持续绽放 斐萃接力增长